Trial Profile
Phase II Study Of Induction Checkpoint Blockade for Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Carboplatin; Cisplatin; Docetaxel; Pemetrexed
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms NEOSTAR
- 09 Jan 2024 Planned End Date changed from 24 Jul 2024 to 31 Dec 2024.
- 09 Jan 2024 Planned primary completion date changed from 24 Jul 2024 to 31 Dec 2024.
- 24 Oct 2023 Results (n=139) assessing and comparing the pathologic patterns of neoadjuvant chemotherapy, immunotherapy and chemotherapy/immunotherapy treated NSCLC and untreated resected NSCLC, presented at the 48th European Society for Medical Oncology Congress.